JP2019514874A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514874A5 JP2019514874A5 JP2018554765A JP2018554765A JP2019514874A5 JP 2019514874 A5 JP2019514874 A5 JP 2019514874A5 JP 2018554765 A JP2018554765 A JP 2018554765A JP 2018554765 A JP2018554765 A JP 2018554765A JP 2019514874 A5 JP2019514874 A5 JP 2019514874A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- hydrogen
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 10
- 239000000651 prodrug Substances 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 claims 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims 1
- 0 *C[C@@]([C@](*)[C@]1*)O[C@]1N(C=CC1)C=C1C(N)=O Chemical compound *C[C@@]([C@](*)[C@]1*)O[C@]1N(C=CC1)C=C1C(N)=O 0.000 description 4
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021117648A JP2021176871A (ja) | 2016-04-20 | 2021-07-16 | Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 |
| JP2022167877A JP7493007B2 (ja) | 2016-04-20 | 2022-10-19 | Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325264P | 2016-04-20 | 2016-04-20 | |
| US62/325,264 | 2016-04-20 | ||
| PCT/US2017/028673 WO2017184885A1 (en) | 2016-04-20 | 2017-04-20 | Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021117648A Division JP2021176871A (ja) | 2016-04-20 | 2021-07-16 | Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514874A JP2019514874A (ja) | 2019-06-06 |
| JP2019514874A5 true JP2019514874A5 (enExample) | 2020-05-28 |
| JP7089480B2 JP7089480B2 (ja) | 2022-06-22 |
Family
ID=60088650
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554765A Active JP7089480B2 (ja) | 2016-04-20 | 2017-04-20 | Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 |
| JP2021117648A Pending JP2021176871A (ja) | 2016-04-20 | 2021-07-16 | Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 |
| JP2022167877A Active JP7493007B2 (ja) | 2016-04-20 | 2022-10-19 | Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021117648A Pending JP2021176871A (ja) | 2016-04-20 | 2021-07-16 | Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 |
| JP2022167877A Active JP7493007B2 (ja) | 2016-04-20 | 2022-10-19 | Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10183036B2 (enExample) |
| EP (1) | EP3445359B8 (enExample) |
| JP (3) | JP7089480B2 (enExample) |
| KR (1) | KR20190008246A (enExample) |
| CN (1) | CN109640984A (enExample) |
| AU (2) | AU2017254657A1 (enExample) |
| BR (1) | BR112018071573A2 (enExample) |
| CA (1) | CA3021571C (enExample) |
| ES (1) | ES2948968T3 (enExample) |
| MX (1) | MX393076B (enExample) |
| NZ (1) | NZ747693A (enExample) |
| WO (1) | WO2017184885A1 (enExample) |
| ZA (1) | ZA201807736B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017011788A1 (en) * | 2015-07-15 | 2017-01-19 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| BR112018002168B1 (pt) | 2015-08-05 | 2023-10-10 | Metro International Biotech, Llc | Composto, ou um estereoisômero ou sal do mesmo, uso do composto e composição que compreende um composto ou um sal farmaceuticamente aceitável do mesmo |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| EP3538099A4 (en) | 2016-11-11 | 2020-06-17 | The Queen's University of Belfast | EFFICIENT AND SCALABLE SYNTHESIS OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS OF THEM, ADENYLYDINUCLEOTIDE CONJUGATES THEREOF AND NEW-WAY CRYSTALS |
| CN110234238B (zh) | 2016-11-29 | 2023-03-28 | 爱荷华大学研究基金会 | Nad前体用于改善母体健康和/或后代健康的用途 |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| WO2018191771A1 (en) * | 2017-04-18 | 2018-10-25 | Victor Chang Cardiac Research Institute | Detection and treatment of congenital malformations |
| SG11201912267SA (en) | 2017-06-19 | 2020-01-30 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| AU2019214858B2 (en) * | 2018-01-30 | 2023-02-02 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| EP3797110A1 (en) * | 2018-05-22 | 2021-03-31 | Jumpstart Fertility Pty Ltd | Amino acid salts of nicotinic acid ribosides as anti-aging agents |
| US11833167B2 (en) | 2018-12-17 | 2023-12-05 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| CN113727987A (zh) * | 2019-02-21 | 2021-11-30 | 可劳迈戴斯有限公司 | 烟酰胺核苷、烟酸核苷、还原型烟酰基核苷化合物和烟酰基核苷化合物衍生物在制品的用途 |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| JP2022534863A (ja) * | 2019-06-05 | 2022-08-04 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 骨格筋の疾患を治療／予防するための還元型ニコチンアミドリボシド |
| US20220323468A1 (en) * | 2019-06-05 | 2022-10-13 | Societe Des Produits Nestle S.A. | Reduced nicotinamideribosides for the treatment/prevention of liver disease |
| WO2020245187A1 (en) * | 2019-06-05 | 2020-12-10 | Société des Produits Nestlé S.A. | Reduced nicotinamideribosides for treating or preventing kidney disease |
| CN110973260A (zh) * | 2019-12-11 | 2020-04-10 | 杨力 | 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用 |
| WO2021123245A1 (en) | 2019-12-19 | 2021-06-24 | Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) | Nad-precursors and dietary restriction for treating age-related medical conditions |
| CN115066246B (zh) * | 2020-03-09 | 2025-11-28 | 雀巢产品有限公司 | 包含用于预防和治疗病毒和细菌感染的还原型烟酰胺核糖核苷的组合物和方法 |
| EP4117677A1 (en) * | 2020-03-09 | 2023-01-18 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions |
| WO2021180741A1 (en) * | 2020-03-09 | 2021-09-16 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions |
| WO2021180732A1 (en) * | 2020-03-09 | 2021-09-16 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions |
| CN114561342B (zh) * | 2020-11-27 | 2024-12-20 | 西安交通大学医学院第一附属医院 | Nad信号通路激动剂在体外胚胎培养中的应用 |
| CN112716969B (zh) * | 2021-01-15 | 2022-11-29 | 江苏恒正合生命科学有限公司 | 治疗阿尔茨海默症的组合物及其制备方法、应用 |
| CA3213831A1 (en) * | 2021-05-05 | 2022-11-10 | Carles Canto Alvarez | Composition and methods using combination of narh and nr to produce intracellular nicotinamide adenine dinucleotide (nad+) |
| CN117545488A (zh) | 2021-05-27 | 2024-02-09 | 麦德龙国际生物科技有限责任公司 | 烟酸单核苷酸及其酯的结晶固体以及其制作和使用方法 |
| JP2024523126A (ja) * | 2021-06-18 | 2024-06-28 | ミトパワー エルエルシー | Ｎｒｈ、ｎａｒｈ、及びそれらの還元誘導体を用いた免疫関連障害、腎障害、肝障害、溶血性障害、及び酸化的ストレス関連障害の処置 |
| EP4422644A4 (en) * | 2021-10-27 | 2025-08-27 | Elysium Health Inc | METHODS OF TREATING MENOPAUSAL SYNDROMES |
| JP7111878B1 (ja) | 2021-10-27 | 2022-08-02 | 旭化成ファーマ株式会社 | ニコチンアミドモノヌクレオチドの製造方法 |
| WO2023150072A1 (en) | 2022-02-01 | 2023-08-10 | Sinclair David A | Compositions and methods for the preservation of plant matter |
| EP4472993A2 (en) * | 2022-02-04 | 2024-12-11 | Elysium Health, Inc. | Ribose linkers and conjugates thereof |
| WO2024118503A1 (en) | 2022-11-28 | 2024-06-06 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7022680B2 (en) * | 2002-05-30 | 2006-04-04 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US7927859B2 (en) | 2003-08-22 | 2011-04-19 | Rice University | High molar succinate yield bacteria by increasing the intracellular NADH availability |
| JP2007521835A (ja) | 2004-02-10 | 2007-08-09 | トラスティーズ・オブ・ダートマウス・カレッジ | ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法 |
| ES2557810T3 (es) | 2004-06-04 | 2016-01-28 | Washington University | Métodos y composiciones para tratar neuropatías |
| ES2670927T3 (es) * | 2005-11-18 | 2018-06-04 | Cornell Research Foundation, Inc. | Composiciones de nicotinoil ribósido y métodos de uso |
| GB201313465D0 (en) | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| CN105873937A (zh) | 2013-10-30 | 2016-08-17 | 可劳迈戴斯有限公司 | 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物 |
| RU2016149767A (ru) | 2014-06-06 | 2018-07-16 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Аналоги никотинамидрибозида и фармацевтические композиции и их применение |
| US10280190B2 (en) * | 2015-03-16 | 2019-05-07 | Chromadex, Inc. | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions |
| WO2017011788A1 (en) | 2015-07-15 | 2017-01-19 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| BR112018002168B1 (pt) | 2015-08-05 | 2023-10-10 | Metro International Biotech, Llc | Composto, ou um estereoisômero ou sal do mesmo, uso do composto e composição que compreende um composto ou um sal farmaceuticamente aceitável do mesmo |
| CN115176998A (zh) * | 2016-04-14 | 2022-10-14 | 可劳迈戴斯有限公司 | 烟酰胺核苷、烟酸核苷、烟酰胺单核苷酸和烟碱基化合物衍生物在婴儿配方中的用途 |
-
2017
- 2017-04-20 US US15/492,952 patent/US10183036B2/en active Active
- 2017-04-20 EP EP17786649.8A patent/EP3445359B8/en active Active
- 2017-04-20 AU AU2017254657A patent/AU2017254657A1/en not_active Abandoned
- 2017-04-20 CA CA3021571A patent/CA3021571C/en active Active
- 2017-04-20 BR BR112018071573-5A patent/BR112018071573A2/pt not_active Application Discontinuation
- 2017-04-20 ES ES17786649T patent/ES2948968T3/es active Active
- 2017-04-20 NZ NZ747693A patent/NZ747693A/en unknown
- 2017-04-20 CN CN201780038245.5A patent/CN109640984A/zh active Pending
- 2017-04-20 JP JP2018554765A patent/JP7089480B2/ja active Active
- 2017-04-20 MX MX2018012849A patent/MX393076B/es unknown
- 2017-04-20 WO PCT/US2017/028673 patent/WO2017184885A1/en not_active Ceased
- 2017-04-20 KR KR1020187033413A patent/KR20190008246A/ko not_active Ceased
-
2018
- 2018-11-16 ZA ZA2018/07736A patent/ZA201807736B/en unknown
-
2021
- 2021-07-16 JP JP2021117648A patent/JP2021176871A/ja active Pending
-
2022
- 2022-08-22 AU AU2022221384A patent/AU2022221384C1/en active Active
- 2022-10-19 JP JP2022167877A patent/JP7493007B2/ja active Active